Receive The Newest Study Notifications

Washington D.C. [USA], Aug 26 (ANI): Pomegranate juice which is known to be rich with nutrients can help in developing brains of infants, according to a study. When it comes to protecting the newborn brain, taking steps to mitigate risk before birth may be critical....

Processa Pharmaceuticals, Inc. (PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have high unmet medical need conditions, announced today the last patient has been enrolled in the...

By Mark Terry for Biospace Biopharma companies large and small are involved in numerous clinical trials. Here’s a look at some of the top stories from last week. Kalytera Therapeutics announced interim data from its Phase II clinical trial of cannabidiol (CBD) for the...

- Trial leads to discovery that onvansertib stops rise in PSA in patients with treatment-resistant, highly-aggressive and difficult-to-treat androgen-receptor variant 7 (AR-V7) tumors - Data demonstrates efficacy of onvansertib in patients showing early signs of...

CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that the first patient in China has been dosed in the Phase I/II bridging study of avapritinib, which was discovered by CStone's partner Blueprint Medicines. This stand-alone registrational bridging study...

California Institute for Regenerative Medicine awarded a $9.28 million grant will support a clinical trial at City of Hope to evaluate chimeric antigen receptor T-cell therapy for patients with HER2-positive breast cancer that spread to the brain. About 20% of breast...

A proposed treatment of HIV that could be administered once every two months rather that a one-month treatment has met the “primary endpoint” in a late-phase clinical trial, ViiV Healthcare announced Thursday. It’s just as effective – “similar efficacy” i.e....

Phase 2 clinical trial of Saroglitazar Magnesium in NAFLD with PCOS Image credit- istock.com Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has initiated a Phase 2 clinical trial for evaluating the effect of Saroglitazar Mg in the...

Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a clinical-stage biopharmaceutical company, today announced dosing of the first patient in its Phase 3 EMERGE efficacy trial of STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of...

Soligenix, Inc. (SNGX) is a late-stage clinical biopharmaceutical company developing treatments in oncology, GI disorders, and biodefense. The company has a number of important near-term catalysts that we believe should be on investor’s radars, including: • Sep. 2019...

Centinel Spine, LLC, the largest privately-held spine company focused on anterior column reconstruction, today announced that the first implantation took place in an Investigational Device Exemption (IDE) study monitored by the Food and Drug Administration (FDA). The...

CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has recently received ethics approval from the Human Research Ethics Committee in Australia for the Phase I clinical trial of CS3002, and Australia's Therapeutic Goods...

CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO, 2019 CSCO Annual Meeting) has accepted three abstracts on the clinical trials of CS1001 (Anti-PD-L1...

 One of the key performance indicators of a patient recruitment service provider is its ability to not only create but maintain a following. This is especially true online, as digital media has become the focus of any modern advertising campaign. Without it, reaching...

MyoKardia, Inc. (NASDAQ: MYOK) today announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for the treatment of hypertrophic cardiomyopathy (HCM). HCM is a progressive disease in which the...

MyoKardia, Inc. (Nasdaq: MYOK) today announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for the treatment of hypertrophic cardiomyopathy (HCM). HCM is a progressive disease in which the...

 Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has randomized its first patient in a phase 2 clinical trial of AR201 for the treatment of egg allergy. AR201, an...

NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, announced that it has treated the first subject in study SNK01-MX03, a phase I clinical trial evaluating SNK, an ex...

Thought leaders from OmniComm Systems and Medable will discuss opportunities that will help clinical professionals become more successful in developing an overall strategy for designing and executing decentralized trials. The featured speakers will provide an overview...

Global clinical trial underway in 11 countries, including US, European, and Eastern European sites to evaluate safety, efficacy and tolerability of orally administered, gut-restricted LANCL2 agonist BT-11, in patients with ulcerative colitis - Landos Biopharma, Inc.,...